IBDV R903/78

Drug Profile

IBDV R903/78

Alternative Names: HC001; HC002; HC003; IBDV-R903/78 - HepC

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HepC
  • Class Anti-infectives; Antineoplastics; Antivirals; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hepatitis B; Hepatitis C
  • Preclinical Dengue; Ebola virus infections; Hepatocellular carcinoma

Most Recent Events

  • 02 May 2017 Preclinical trials in Dengue in Hungary, USA (PO) before May 2017 (HepC pipeline, May 2017)
  • 02 May 2017 Preclinical trials in Ebola virus infections in USA, Hungary (PO) before May 2017 (HepC pipeline, May 2017)
  • 02 May 2017 Preclinical trials in Hepatocellular carcinoma in Hungary, USA (PO) before May 2017 (HepC pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top